Recent Updates
Recently added Catalysts

Pneumococcal 13-valent Conjugate Vaccine

Phase 3

Healthy Volunteers (Meningococcal Infection) | Monoclonal antibody | Other |Sanofi|Last Updated: Dec 14, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment2,797

FDA Designations

No designations recorded

Clinical trial landscape

Pneumococcal 13-valent Conjugate Vaccine · 1 trial · 1 indication

Phase 3 1
NCT03673462Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersHealthy Volunteers (Meningococcal Infection)
COMPLETED2,797 Analytics
PHASE3COMPLETED
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
Healthy Volunteers (Meningococcal Infection)Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
Within 30 minutes post-any vaccination

An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Immediate adverse events are unsolicited systemic adverse events occurring in the 30 minutes after injection. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Solicited Injection Site Reactions
Within 7 days post any vaccination

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited injection site reactions included Injection site tenderness, Injection site erythema, and Injection site swelling and were planned to be collected and reported for each vaccine separately; and not planned to be collected for Rotavirus vaccine as the vaccine was administered orally, and no injection site reactions were expected to occur. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Solicited Systemic Reactions
Within 7 days post-any vaccination

A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Unsolicited Adverse Events
Within 30 days post any vaccination

An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious adverse events (SAEs) and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)

A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Medically Attended Adverse Event (MAAEs)
From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)

A MAAE was defined as a new onset of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a health care provider's office or Emergency Department. Reported AEs for each arm were presented as pre-specified in protocol.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group 1: MenACYW Conjugate VaccineEXPERIMENTALHealthy infants aged greater than equal to (\>=) 42 to less than equal to (\<=) 89 days (at the time of enrollment) received MenACYW Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
Group 2: MENVEO®ACTIVE_COMPARATORHealthy infants aged \>= 42 to \<= 89 days (at the time of enrollment) received MENVEO® Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.

Interventions

NameTypeDescription
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)BIOLOGICALPharmaceutical form: Liquid solution. Route of administration: Intramuscular
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)BIOLOGICALPharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b VaccineBIOLOGICALPharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
Pneumococcal 13-valent Conjugate VaccineBIOLOGICALPharmaceutical form: Suspension for injection Route of administration: Intramuscular
Rotavirus VaccineBIOLOGICALPharmaceutical form: Oral solution Route of administration: Oral
Hepatitis B VaccineBIOLOGICALPharmaceutical form: Suspension for injection Route of administration: Intramuscular
Measles, Mumps, and Rubella Virus VaccineBIOLOGICALPharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
Varicella Virus VaccineBIOLOGICALPharmaceutical form: Suspension for injection Route of administration: Subcutaneous
Unlock Study Design Details

Eligibility Criteria

Age Range42 Days to 89 Days
SexALL
Healthy VolunteersYes
Study Sites69

Inclusion criteria: * Aged \>= 42 to \<= 89 days on the day of the first study visit. * Healthy infants as determined by medical history, physical examination, and judgment of the investigator. * Informed consent form was signed and dated by the parent(s) or guardian (and by an independent witness ...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria

Frequently asked questions about Pneumococcal 13-valent Conjugate Vaccine

What is Pneumococcal 13-valent Conjugate Vaccine used for?

Pneumococcal 13-valent Conjugate Vaccine is an investigational vaccine being studied in healthy volunteers for the prevention of meningococcal infection. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.

Who makes Pneumococcal 13-valent Conjugate Vaccine?

Pneumococcal 13-valent Conjugate Vaccine is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The company is conducting clinical trials to evaluate the vaccine's safety and efficacy.

What phase is Pneumococcal 13-valent Conjugate Vaccine in?

Pneumococcal 13-valent Conjugate Vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved for use. The Phase 3 trial has been completed, with results expected to inform further regulatory submissions.

What clinical trials is Pneumococcal 13-valent Conjugate Vaccine in?

Pneumococcal 13-valent Conjugate Vaccine has been studied in one completed Phase 3 clinical trial, identified as NCT03673462. This trial evaluated the safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.

Is Pneumococcal 13-valent Conjugate Vaccine the same as a quadrivalent meningococcal conjugate vaccine?

Pneumococcal 13-valent Conjugate Vaccine is not the same as a quadrivalent meningococcal conjugate vaccine. The clinical trial NCT03673462 evaluated a quadrivalent meningococcal conjugate vaccine, not the pneumococcal vaccine. The pneumococcal vaccine is a separate investigational product.